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Repeat Tdap Vaccination and Adverse Birth Outcomes
Lakshmi Sukumaran, MD, MPH and Saad B. Omer, MBBS, MPH, PhD
Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, Georgia 
(Sukumaran); Hubert Department of Global Health, Emory University, Atlanta, Georgia (Omer).
In Reply Ms Zhu and colleagues express concerns regarding potential bias and confounding 
in the study evaluating the safety of repeated tetanus-containing vaccines in pregnancy.
First, they point to the accuracy of methods for identifying gestational age. The pregnancy 
episode algorithm was used to identify live births in our study but was not the method used 
for identifying gestational age. The validation data presented were specific to the pregnancy 
episode algorithm for identifying live births. We stated in the article that we limited the 
cohort for birth outcomes to “records that contained information on the neonate (ie, weight 
and gestational age).” In the Vaccine Safety Datalink, gestational age data come from 
electronic medical record and state birth registry data, which are based on clinician 
assessment. The clinician uses all available data to determine this estimate, including 
estimated due date based on ultrasound and last menstrual period data and can adjust this 
estimate based on the infant’s appearance at birth.
Zhu and colleagues also raise concerns about risk factors that were used in the analysis of 
birth outcomes. Despite the change in direction of the relative risk with adjustment, both the 
unadjusted and adjusted risk estimates were nonsignificant, and it is inappropriate to 
overinterpret nonsignificant point estimates on either side of the null. After adjustment for 
adequacy of prenatal care, comorbidities, and pregnancy complications (which were 
clinically similar between the groups compared), in addition to gestational age at 
vaccination, health care site, maternal age, and length of enrollment, we still did not find an 
association. These adjustments strengthen the overall findings, especially because we had 
substantial statistical power to detect a difference in birth outcomes. A healthy user effect 
would not be expected, as all of the women in our study were vaccinated, and women during 
their prime childbearing years are generally healthy and seek preventive care during 
pregnancy.
Finally, Zhu and colleagues suggest that because most Tdap vaccinations in our study were 
given in the third trimester, our results might not apply to vaccinations given earlier in 
pregnancy. Although it is true that 67.4% of the pregnancies had Tdap in the third trimester, 
there were 9505 pregnancies in which vaccinations were given in the first or second 
trimester. The Advisory Committee on Immunization Practices currently recommends Tdap 
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at any time during pregnancy with a preference for third trimester administration to “provide 
the highest concentration of maternal antibodies to be transferred closer to birth.”1 This 
optimal timing for administration corresponds to the majority of vaccinations given in our 
study. Therefore, our findings are applicable to pregnant women whose clinicians are 
following recommendations. However, we agree that additional data for first trimester 
vaccination will further strengthen the evidence base regarding Tdap safety in early 
pregnancy.
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